Basal Insulin Therapies for Diabetes Management
Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, and Thomas C. Blevins, MD, ECNU, FACE, FNLA, review FDA-approved basal insulins for the management of diabetes.
Results of INSTRIDE Studies for Diabetes Management
Experts in diabetes management discuss data from key clinical trials—INSTRIDE 1, INSTRIDE 2, and INSTRIDE 3—and evaluate the use of insulin glargine-yfgn as an interchangeable product with biologics.
Role of Interchangeable Biosimilars in the Management of Diabetes
Thomas C. Blevins, MD, ECNU, FACE, FNLA, provides an overview of biosimilars and discusses interchangeability status among biosimilars such as for insulin glargine-yfgn for the management of diabetes.
Future Directions for the Use of Biosimilars in Diabetes
Drs Thomas C. Blevins and Diana Isaacs share insight on unmet needs and the future treatment landscape of biosimilars in the treatment of patients with diabetes.
Challenges to Biosimilar Adoption of Insulin Glargine-yfgn
Thomas C. Blevins, MD, ECNU, FACE, FNLA, leads the discussion on potential challenges to the adoption of biosimilars in clinical practice, such as for insulin glargine-yfgn in diabetes management, and discusses the importance of patient and provider education.
Impact of Interchangeable Insulin Biosimilars on Cost of Biologics
Thomas C. Blevins, MD, ECNU, FACE, FNLA, and Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discuss the impact of interchangeable insulin biosimilars on biologic products in the marketplace for diabetes management.
2 Commerce Drive Cranbury, NJ 08512